Jeffrey David Jensen, Claudia Bank, Li Jiang
The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to qu ...
Academic Press Ltd- Elsevier Science Ltd2016